Search

Displaying results 1631 - 1640 of 7687 in total
  1. Drug

    Lorpiprazole

    go.drugbank.com/drugs/DB09195
    Approved

    Lorpiprazole is a serotonin antagonist and reuptake inhibitor used for the treatment of major depressive disorder. It is a piperazinyl-triazole derivative.

  2. Drug

    Guanethidine

    go.drugbank.com/drugs/DB01170
    ApprovedWithdrawn

    An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves.

  3. Drug

    Trazodone

    go.drugbank.com/drugs/DB00656
    ApprovedInvestigational

    [T646] It was initially granted FDA approval in 1981.[L3484]

    Products: Nu-trazodone-D - Tab 150mg, Trazodone-150 D
  4. Drug

    Benzoin

    go.drugbank.com/drugs/DB14020
    ApprovedWithdrawn

    Benzoin is an FDA-approved colour additive used for marking fruits and vegetables.

  5. Drug

    Revumenib

    go.drugbank.com/drugs/DB18515
    ApprovedInvestigational

    It was approved by the FDA in November 2024 for the treatment of leukemia with KMT2A aberrations,[L51868,L51863] becoming the first menin inhibitor to receive FDA approval. … [A264688] Revumenib is an oral small molecule menin inhibitor that prevents the interaction between menin and aberrant KMT2A.

  6. Drug

    Daratumumab

    go.drugbank.com/drugs/DB09331
    ApprovedInvestigational

    [A199002] Daratumumab was granted FDA approval on 16 November 2015. … Daratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab.

  7. Drug

    Blonanserin

    go.drugbank.com/drugs/DB09223
    Investigational

    Blonanserin is an atypical antipsychotic approved in Japan in January, 2008.

    Categories: Dopamine D2 Receptor Antagonists
  8. Drug

    Glycerol phenylbutyrate

    go.drugbank.com/drugs/DB08909
    ApprovedInvestigational

    FDA approved on February 1, 2013.

  9. Target

    NADPH-flavin oxidoreductase

    go.drugbank.com/bio_entities/BE0002629
    TargetVibrio harveyi

    Catalyzes the NADPH-dependent reduction of FMN to FMNH(2). Involved in bioluminescence by providing FMNH(2) to luciferase.

    Synonyms: FRP
  10. Drug

    Rozanolixizumab

    go.drugbank.com/drugs/DB14919
    ApprovedInvestigational

    an action potential. … [L47122] This is due to the efficacy demonstrated in the pivotal Phase 3 MycarinG study (NCT03971422).[L47122] Rozanolixizumab was also approved by the European Commission on January 5, 2024.[L50973]